Page last updated: 2024-11-12
3,5-diethoxy-4-aminomethylpyridine
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
3,5-diethoxy-4-aminomethylpyridine: reversible inhibitor of benzylamine oxidase [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 10445774 |
| CHEMBL ID | 1188790 |
| SCHEMBL ID | 343169 |
| MeSH ID | M0249536 |
Synonyms (7)
| Synonym |
|---|
| (3,5-diethoxypyridin-4-yl)methanamine |
| bdbm50161143 |
| (3,5-diethoxypyridin-4-yl)methylamine dihydrochloride |
| SCHEMBL343169 |
| CHEMBL1188790 |
| 4-pyridinemethanamine, 3,5-diethoxy- |
| 3,5-diethoxy-4-aminomethylpyridine |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Bioassays (2)
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID1067359 | Oral bioavailability in rat | 2014 | Bioorganic & medicinal chemistry, Mar-01, Volume: 22, Issue:5 | Synthesis of 2,6-disubstituted benzylamine derivatives as reversible selective inhibitors of copper amine oxidases. |
| AID1067360 | Half life in rat | 2014 | Bioorganic & medicinal chemistry, Mar-01, Volume: 22, Issue:5 | Synthesis of 2,6-disubstituted benzylamine derivatives as reversible selective inhibitors of copper amine oxidases. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
Research
Studies (8)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 6 (75.00) | 18.2507 |
| 2000's | 1 (12.50) | 29.6817 |
| 2010's | 1 (12.50) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 12.16
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.16) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 8 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||